Innovent Chipscreen Biosciences to assess combination therapy in colorectal cancer patients

Innovent, Chipscreen Biosciences to assess combination therapy in colorectal cancer patients

Under the collaboration, the firms will evaluate the safety and tolerability of the combination therapy of Innovent’s Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death

More From BioPortfolio on "Innovent, Chipscreen Biosciences to assess combination therapy in colorectal cancer patients"